Lilly Strikes Out With The FDA For Second Time This Year With Mirikizumab CRL
Agency Denied Donanemab Accelerated Approval In January
Executive Summary
With mirikizumab delayed until Lilly overcomes the FDA’s manufacturing concerns, the company has fallen behind on its goal of five approvals in 2023.
You may also be interested in...
Lilly Plans Mirikizumab Filing For Crohn’s After Phase III Success
Mirikizumab, already under review at the FDA for ulcerative colitis, bests placebo on two primary endpoints in Crohn’s. Lilly hopes to beat AbbVie’s Skyrizi, already approved for Crohn's, to market in UC.
Lilly’s Latest Leadership Shuffle Gives CSO Skovronsky Immunology Oversight
Lilly Diabetes president Mike Mason is retiring, prompting a shifting of responsibilities among the executive team as the company gears up for key product approvals.
AbbVie’s Skyrizi Bests Stelara Head-To-Head In Crohn’s
Data showing superiority on endoscopic remission and non-inferiority on clinical remission could position AbbVie’s IL-23 inhibitor to move ahead of Stelara in treatment paradigm.